Rigel Pharmaceuticals, Inc. Aktie News

SOUTH SAN FRANCISCO, Calif. , May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m.

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors   Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, ...

Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Ka...

First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-...

SOUTH SAN FRANCISCO, Calif. , April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025.

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

SOUTH SAN FRANCISCO, Calif. , April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NAS...